196 related articles for article (PubMed ID: 25582663)
1. Insight into the interactive residues between two domains of human somatic Angiotensin-converting enzyme and Angiotensin II by MM-PBSA calculation and steered molecular dynamics simulation.
Guan SS; Han WW; Zhang H; Wang S; Shan YM
J Biomol Struct Dyn; 2016; 34(1):15-28. PubMed ID: 25582663
[TBL] [Abstract][Full Text] [Related]
2. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
3. Simulated interactions between angiotensin-converting enzyme and substrate gonadotropin-releasing hormone: novel insights into domain selectivity.
Papakyriakou A; Spyroulias GA; Sturrock ED; Manessi-Zoupa E; Cordopatis P
Biochemistry; 2007 Jul; 46(30):8753-65. PubMed ID: 17605472
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
[TBL] [Abstract][Full Text] [Related]
5. Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides.
Masuyer G; Schwager SL; Sturrock ED; Isaac RE; Acharya KR
Sci Rep; 2012; 2():717. PubMed ID: 23056909
[TBL] [Abstract][Full Text] [Related]
6. Transforming Non-Selective Angiotensin-Converting Enzyme Inhibitors in C- and N-domain Selective Inhibitors by Using Computational Tools.
Alfaro S; Navarro-Retamal C; Caballero J
Mini Rev Med Chem; 2020; 20(14):1436-1446. PubMed ID: 31889494
[TBL] [Abstract][Full Text] [Related]
7. Development of domain-selective angiotensin I-converting enzyme inhibitors.
Redelinghuys P; Nchinda AT; Sturrock ED
Ann N Y Acad Sci; 2005 Nov; 1056():160-75. PubMed ID: 16387685
[TBL] [Abstract][Full Text] [Related]
8. [Angiotensin converting enzyme domain structure and properties].
Kugaevskaia EV
Biomed Khim; 2005; 51(6):567-80. PubMed ID: 16521820
[TBL] [Abstract][Full Text] [Related]
9. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.
Corradi HR; Chitapi I; Sewell BT; Georgiadis D; Dive V; Sturrock ED; Acharya KR
Biochemistry; 2007 May; 46(18):5473-8. PubMed ID: 17439247
[TBL] [Abstract][Full Text] [Related]
10. [Angiotensin converting enzyme: the antigenic properties of the domain, role in Alzheimer's disease and tumor progression].
Kugaevskaya EV; Timoshenko OS; Solovyeva NI
Biomed Khim; 2015; 61(3):301-11. PubMed ID: 26215407
[TBL] [Abstract][Full Text] [Related]
11. Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype.
van Esch JH; van Gool JM; de Bruin RJ; Payne JR; Montgomery HE; Hectors M; Deinum J; Dive V; Jan Danser AH
J Hypertens; 2008 Apr; 26(4):706-13. PubMed ID: 18327080
[TBL] [Abstract][Full Text] [Related]
12. Fibrosis and myocardial ACE: possible substrate and independence from circulating angiotensin II.
Sun Y; Weber KT
J Card Fail; 1994 Oct; 1(1):81-9. PubMed ID: 9420636
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design.
Corradi HR; Schwager SL; Nchinda AT; Sturrock ED; Acharya KR
J Mol Biol; 2006 Mar; 357(3):964-74. PubMed ID: 16476442
[TBL] [Abstract][Full Text] [Related]
14. Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme.
Dalkas GA; Marchand D; Galleyrand JC; Martinez J; Spyroulias GA; Cordopatis P; Cavelier F
J Pept Sci; 2010 Feb; 16(2):91-7. PubMed ID: 20014331
[TBL] [Abstract][Full Text] [Related]
15. Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors.
Polakovičová M; Jampílek J
Med Chem; 2019; 15(6):574-587. PubMed ID: 31084594
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory antibodies to human angiotensin-converting enzyme: fine epitope mapping and mechanism of action.
Skirgello OE; Balyasnikova IV; Binevski PV; Sun ZL; Baskin II; Palyulin VA; Nesterovitch AB; Albrecht RF; Kost OA; Danilov SM
Biochemistry; 2006 Apr; 45(15):4831-47. PubMed ID: 16605251
[TBL] [Abstract][Full Text] [Related]
17. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme open for business: structural insights into the subdomain dynamics.
Cozier GE; Lubbe L; Sturrock ED; Acharya KR
FEBS J; 2021 Apr; 288(7):2238-2256. PubMed ID: 33067882
[TBL] [Abstract][Full Text] [Related]
19. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
[TBL] [Abstract][Full Text] [Related]
20. Insights into AT1 receptor activation through AngII binding studies.
Matsoukas MT; Potamitis C; Plotas P; Androutsou ME; Agelis G; Matsoukas J; Zoumpoulakis P
J Chem Inf Model; 2013 Nov; 53(11):2798-811. PubMed ID: 24053563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
